KRAS and neoplasm: Most recently, KRAS G12D inhibitor MRTX1133 have been shown to inhibit oncogenic KRAS signalling and reduce tumour growth via the inactivation of ERK pathway (Mao et al., 2022; Wang et al., 2022).